Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,981,339 | 6,086,785 | 3,882,029 | 3,160,094 | 2,907,681 |
| Depreciation Amortization | 777,472 | 2,655,625 | 2,698,340 | 1,676,093 | 944,627 |
| Accounts receivable | N/A | -195,430 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | 611,029 | N/A | N/A | N/A |
| Other Working Capital | -2,605,746 | 333,963 | -263,827 | -290,021 | -758,117 |
| Other Operating Activity | -88,681 | -335,200 | 159,002 | 698,058 | 316,665 |
| Operating Cash Flow | $64,384 | $9,156,771 | $6,475,544 | $5,244,224 | $3,410,856 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -55,881 | 118,742 | -142,514 | -74,075 | -60,381 |
| PPE Investments | -274,545 | -1,233,189 | -815,038 | -532,332 | -289,829 |
| Net Acquisitions | -7,289 | -3,898,709 | -3,591,112 | -15,066 | 1,342 |
| Purchase Of Investment | N/A | N/A | -1,178 | N/A | N/A |
| Sale Of Investment | 1,215 | N/A | 135,447 | N/A | N/A |
| Purchase Sale Intangibles | -354,722 | -1,136,711 | -796,193 | -733,212 | -496,466 |
| Other Investing Activity | -159,139 | -5,836,934 | -5,281,255 | -4,573,787 | -4,472,219 |
| Investing Cash Flow | $-495,638 | $-10,850,090 | $-9,695,649 | $-5,195,259 | $-4,821,087 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 670,570 | 1,262,875 | -4,955,004 | N/A | N/A |
| Debt Issued | N/A | 1,267,823 | N/A | N/A | 12,351,270 |
| Debt Repayment | -174,931 | -1,971,619 | -10,600 | -3,767 | N/A |
| Common Stock Issued | 9,718 | 30,923 | 29,445 | 25,110 | 22,811 |
| Common Stock Repurchased | -2,430 | N/A | N/A | -3,767 | -6,709 |
| Dividend Paid | -674,214 | -4,288,333 | -3,313,151 | -2,646,594 | -1,277,394 |
| Other Financing Activity | -215,020 | 4,716,301 | 10,794,536 | 7,006,946 | -391,808 |
| Financing Cash Flow | $-386,306 | $1,017,969 | $2,545,226 | $4,377,929 | $10,698,170 |
| Exchange Rate Effect | -37,659 | 188,009 | 124,847 | 104,207 | 16,102 |
| Beginning Cash Position | 4,160,690 | 4,723,721 | 4,498,018 | 4,792,244 | 5,121,650 |
| End Cash Position | 3,305,471 | 4,236,382 | 3,947,986 | 9,323,343 | 14,425,690 |
| Net Cash Flow | $-855,219 | $-487,339 | $-550,033 | $4,531,100 | $9,304,041 |
| Free Cash Flow | |||||
| Operating Cash Flow | 64,384 | 9,156,771 | 6,475,544 | 5,244,224 | 3,410,856 |
| Capital Expenditure | -283,048 | -1,413,777 | -830,349 | -539,865 | -297,880 |
| Free Cash Flow | -218,664 | 7,742,994 | 5,645,195 | 4,704,359 | 3,112,976 |